What science can do
Annual Report 和 形成20 f年报
Information 2021
Our Annual Report
We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do. In our Annual Report we report on the progress we made in 2021 in pushing the boundaries of science to deliver life-changing medicines.
Reflecting this increased confidence, the Board has approved an increase in the annualised dividend.
Leif Johansson, 椅子
7月, we completed our l和mark acquisition of Alexion, which established our rare disease capability.
Pascal Soriot, Chief Executive Officer
Strategic overview
We are a global pharmaceutical business with a science-led 和 patient-focused value proposition committed to excellence in the research, development 和 commercialisation of prescription medicines.
Inspired by our Values 和 what science can do, we are focused on accelerating the delivery of life-changing medicines that create enduring value for 病人 和 society.
Accelerate Innovative Science
Accelerating the next wave of new molecular entities, building our capabilities in immunology 和 rare diseases, pursuing new scientific modalities 和 driving R&D生产力.
管道 progression events
321 •
(2020: 36)
1. 26 against our Group scorecard for determining annual bonus. 2021 total includes Alexion.
2. 25 against our Group scorecard for determining annual bonus.
3. 17 against our Group scorecard for determining annual bonus.
Regulatory events
491 •
(2020:53)
1. 37 against our Group scorecard for determining annual bonus. 2021 total includes Alexion.
2. 43 against our Group scorecard for determining annual bonus.
3. 37 against our Group scorecard for determining annual bonus.
Deliver Growth 和 Therapy Area Leadership
Meeting our growth 和 profitability goals through successful innovation 和 commercial excellence, as well as completing the Alexion acquisition.
总收入*
$37,417m •
(2020:$26,617m)
*总营收 consists of Product Sales 和 Collaboration Revenue.
Be a Great Place to Work
Contributing to the enterprise 和 to society, with a focus on inclusion 和 diversity, lifelong learning, improving access to healthcare, environmental protection, 和 ethics 和 transparency, as well as delivering our Ambition Zero Carbon programme.
Employee belief that AstraZeneca is a great place to work1
85%
(2020:89%)
1. Source: November Pulse survey for each year.
可持续性 scorecard performance2
83% •
(2020: 93%)
2. A Green rating = more than 70% of our categories are rated green. Each category consists of several KPIs. We have 14 priority goals. Achievement of <9 is Red; 9 or 10 is Amber; 11 or 12 is Green; 和 13 or 14 is Blue.
• Used for remuneration of Executive Directors
// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.
Disease Area Review
We have a diversified portfolio with broad coverage across primary, specialty care 和 rare disease.
肿瘤学
We are leading a revolution in oncology to redefine cancer care.
Our ambition is to follow the science to discover, develop 和 deliver life-changing treatments that increase the potential for cure.
We strive to push the boundaries of science to change the practice of medicine 和 transform the lives of 病人 living with cancer.
BioPharmaceuticals
We want to change the lives of billions of people living with chronic diseases for the better, enabling them to live life without limits.
Our ambition is to stop the progress of these often degenerative, debilitating 和 life-threatening conditions, achieve remission 和, 有一天,, 治愈他们.
BioPharmaceuticals is responsible for Cardiovascular, Renal & Metabolism 和 呼吸 & 免疫学.
罕见的疾病
On 21 July 2021, we completed the acquisition of Alexion Pharmaceuticals, Inc. 和 created Alexion, AstraZeneca 罕见的疾病, a new disease area within our company.
Our mission is to transform the lives of people affected by rare diseases 和 devastating conditions. By underst和ing 病人’ unique needs, we can research 和 develop innovative medicines, support access 和 advocate for the rare disease community.
新型冠状病毒肺炎
We are working to defeat the 新型冠状病毒肺炎 p和emic.
与 Vaxzevria 和 Evusheld, we are significantly contributing to global public health.
AstraZeneca 和 our global partners released for supply 2.5 billion vaccine doses to over 180 countries. Approximately two-thirds of these went to LMICs, 和 more than 247 million doses have been delivered to 130 countries through the COVAX Facility in 2021.
可持续性 Highlights
Our ambition is to harness the power of science 和 innovation in ways that have a positive impact on society, 病人, healthcare systems 和 the environment, through actions for the long term.
Through our flagship $1 billion Ambition Zero Carbon programme, we are on track to reduce greenhouse gas emissions from our global operations by 98% by 2026 和 halve our entire value chain footprint by 2030, on the way to a 90% reduction by 2045.
Access to healthcare
We are working towards a future where everyone can have access to sustainable health solutions for life-changing treatment 和 care.
Achievements in 2021:
31.0m
超过199,000 healthcare workers 和 others trained since 2010 和 over 31 million people reached through Access to Healthcare programmes.
Environmental protection
We aim to demonstrate global leadership by minimising our environmental impact across all our activities 和 products. Becoming increasingly circular, we are designing out waste 和 pollution, keeping products 和 materials in use, 和 maximising resource efficiency.
Achievements in 2021:
59%
59% reduction in Scope 1 和 2 greenhouse gas emissions since 2015.
Ethics 和 transparency
We seek to create positive societal impact 和 embed ethical behaviour in all our business activities, markets 和 value chain. We do this by promoting ethical, transparent 和 inclusive policies within our company as well as across all our partners 和 suppliers.
Achievements in 2021:
48.1%
48.1% of senior middle management roles 和 above are held by women.
Achieve Group Financial Targets
Cash generation is a key driver of long-term shareholder returns 和 facilitates reinvestment in our pipeline, which is critical for delivering new medicines 和 future value.
Net cash flow from operating activities
$6.0bn •
Up 24% at actual rate of exchange to $6.0bn
报告每股收益
$0.08
Down 97% at actual rate of exchange to $0.08
(down 84% at CER)
核心每股收益
$5.29 •
Up 32% at actual rate of exchange to $5.29
(CER上涨37%)
• Used for remuneration of Executive Directors
// Denotes a scale break. All bar chart scales start from zero. We use a scale break where charts of a different magnitude, but the same unit of measurement, are presented alongside each other.
Annual Report 下载
